Systemic Lupus Erythematosus Market
Number of pages: 100 | Report Format: PDF | Published date: February 22, 2023
Historical Years – 2020 | Base Year – 2021 | Forecasted Years – 2022-2030
|
Report Attribute |
Details |
|
Market Size Value in 2021 |
US$ 2.46 billion |
|
Revenue Forecast in 2030 |
US$ 4.67 billion |
|
CAGR |
7.2% |
|
Base Year For Estimation |
2021 |
|
Forecast Period |
2022-2030 |
|
Historical Year |
2020 |
|
Segments Covered |
Treatment Type, Route of Administration, Distribution Channel, and Region |
|
Regional Scope |
North America, Europe, Asia Pacific, and the Rest of the World (RoW) |
According to the deep-dive market assessment study by Growth Plus Reports, the global systemic lupus erythematosus market was valued at US$ 2.46 billion in 2021 and is expected to register a revenue CAGR of 7.2% to reach US$ 4.67 billion by 2030.
Systemic Lupus Erythematosus Market Fundamentals
Systemic lupus erythematosus (SLE) is an autoimmune condition characterized by the immune system’s attack on its own tissues, which results in extensive tissue destruction and inflammation in the affected organs. The brain, lungs, kidneys, blood vessels, joints, and skin are usually impacted. Though lupus cannot be cured, it can be controlled with the help of medical procedures and dietary adjustments. Moreover, the exact origins of SLE are not known. The hormonal, genetic, and environmental factors are considered to play a significant role in the disease. A patient suffering from SLE can show a wide range of symptoms, such as weariness, skin rashes, fevers, and discomfort or swelling in the joints. The list of additional symptoms includes sun sensitivity, oral ulcers, arthritis, lung, heart, and kidney issues, seizures, psychosis, and blood cell and immunological abnormalities. Every age group is susceptible to SLE.
According to an article published by Frontiers Media S.A. in 2021, the SLE prevalence rates varied between sexes, age groups, geographic regions, and ethnic backgrounds, ranging from 4.8 to 90 per 100,000 individuals. Those of African or Asian descent had incidence and prevalence rates around 2-3 times greater than those of the white population. In addition, a 2022 report by CDC stated that inadequate access to care, delayed diagnosis, less effective therapies, and poor adherence to therapeutic regimens worsened SLE’s detrimental consequences, leading to more complications and a higher possibility of mortality. People of all ages, including children, are susceptible to SLE. Hence, when SLE risk factors rise, so does the demand for SLE medications, thus fueling the market’s expansion.
[5754675]
Systemic Lupus Erythematosus Market Dynamics
The global market for systemic lupus erythematosus is growing owing to the factors such as rising healthcare costs, growing female population, rapid urbanization, favorable government policies, and increasing SLE disease prevalence. Various governments and private groups have launched several campaigns to raise awareness of SLE. Several research institutions are offering medicines and treatments to SLE patients with government funding.
All vaccines, medical devices, and beneficial drugs have historically undergone comprehensive testing in clinical trials to assure their safety and viability in treating the disease. The market is also likely to grow rapidly during the forecast period as a result of ongoing trends, such as an increase in clinical trials, the rise in the use of stem cell therapy, and increase in public awareness. Stem cell therapy is gaining traction as one of the most promising emerging areas of medicine for the treatment of lupus, particularly for patients who do not respond well to more conventional forms of treatment.
One of the biggest obstacles for the market for systemic lupus erythematosus is a stringent regulatory environment.
Systemic Lupus Erythematosus Market Ecosystem
The global systemic lupus erythematosus market has been analyzed from four perspectives: treatment type, route of administration, distribution channel, and region.
Systemic Lupus Erythematosus Market by Treatment Type
[774564]
Based on treatment type, the global systemic lupus erythematosus market is segmented into antimalarial drugs, non-steroidal anti-inflammatory drugs, cytotoxic and immunosuppressive drugs, biologics, and others.
The cytotoxic and immunosuppressive drugs segment is further sub-segmented into cyclosporine, cyclophosphamide, methotrexate, mycophenolate mofetil, and tacrolimus. The biologics segment is further sub-segmented into B-cell modulators, T-cell modulators, pro-inflammatory, and cytokine Inhibitors.
In 2021, the cytotoxic and immunosuppressive drugs segment accounted for the major revenue share of the global market. The widespread use of methotrexate, which is inexpensive and readily available, is responsible for the segment’s expansion. Moreover, the biologics segment is anticipated to experience the highest revenue CAGR during the projection period due to the increase in the launch of novel biologics with increased efficacy.
Systemic Lupus Erythematosus Market by Route of Administration
Based on the route of administration, the global systemic lupus erythematosus market is segmented into parenteral, oral, and topical.
The oral segment accounted for the majority of the global market revenue share in 2021. Small molecule medications that can be administered orally are still the most popular form of treatment for SLE. A higher revenue CAGR is anticipated for the subcutaneous segment during the forecast period. One of the main growth factors for the market is the recent approval of the subcutaneous formulation of benlysta and rituximab in several countries, including the U.S. and numerous countries in Europe.
Systemic Lupus Erythematosus Market by Distribution Channel
Based on the distribution channel, the global systemic lupus erythematosus market has been segmented into hospital pharmacy, retail pharmacy, and online pharmacy.
Although many drugs for the management of SLE are available in retail pharmacies, many patients still visit hospitals for proper professional diagnosis and treatments. Hence, the hospital pharmacy segment captures the majority of the global systemic lupus erythematosus market revenue share.
Systemic lupus erythematosus Market by Region
Based on the region, the global systemic lupus erythematosus market has been segmented into North America, Europe, Asia Pacific, and the rest of the world.
North America accounted for the leading revenue share of the market in 2021. This is ascribed to a rising prevalence of SLE, coverage for specialty medications, and improved healthcare infrastructure.
In 2021, Europe accounted for the second-largest position in the global market. This is attributed to the fact that the Benlysta add-on medication for the treatment of active SLE was originally approved in the five major European nations, which included the United Kingdom, Germany, Spain, Italy, and France. Additionally, since belimumab is offered in both forms, there is a larger adoption of the drug due to improved coverage policies.
The markets in Latin America and middle east & Africa are likely to grow at a sluggish revenue CAGR due to the low ratio of rheumatologists to the population, which is likely to hinder the SLE treatment and early diagnosis in these regions. Belimumab is available in these regions. However, the high cost and unfavorable reimbursement environment prevent patients from accessing the drug. The majority of patients in low-income countries turn to the public healthcare system, which often lacks high-quality medical facilities.
Systemic Lupus Erythematosus Market Competitive Landscape
The prominent players operating in the global systemic lupus erythematosus market are:
Systemic Lupus Erythematosus Market Strategic Developments
The global systemic lupus erythematosus market is expected to grow at a revenue CAGR of 7.2% during the forecast period.
GlaxoSmithKline Plc, AstraZeneca, Sanofi, Anthera Pharmaceuticals, Inc., and Bristol-Myers Squibb., are a few key players in the global systemic lupus erythematosus market.
The immunosuppressants segment dominated the global systemic lupus erythematosus market in 2021.
The Asia Pacific market is expected to register the highest revenue growth during the forecast period.
*Insights on financial performance are subject to the availability of information in the public domain